Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Lowers Price Target to $67
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has maintained a Strong Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) but has reduced the price target from $93 to $67.

December 15, 2023 | 9:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals' Strong Buy rating is maintained by Raymond James, yet the price target is lowered from $93 to $67.
The reduction in price target from $93 to $67 by a reputable analyst firm like Raymond James could lead to a negative short-term sentiment among investors, potentially causing a decrease in the stock price. However, the maintenance of a Strong Buy rating indicates a positive long-term outlook, which might mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100